MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
NURO - Neurometrix Inc.
$4.18
0.13(3.21%)9:00:00 PM 1/22/2021
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
Stock Chart

Summary:

  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 73. A high level of RSI indicates the stock is overbought.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/22/2021NURO
    NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call

    WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2021 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using th...

    10/22/2020NURO
    NeuroMetrix Reports Q3 2020 Financial Results

    WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions. Q3 2020 Highlights: * Revenue of $2.0 million was about level with $2.1 million in Q3 2019 reflecting an improving economic environment and broadening delivery of health care services. ...

    10/15/2020NURO
    NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call

    WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on October 22, 2020 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation ...

    09/22/2020NURO
    NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device

    Quell® Watch App The Quell Watch app gives a Quell user the ability to control and monitor their pain relief from their Apple Watch®WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a wearable, transcutaneous electrical nerve stimulation (TENS) device for knee, foot and leg pain that is available over-the-counter. It can be used during the day while ac...

    09/21/2020NURO
    NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology

    WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation." The patent covers core Quell technology that regulates electrical stimulation based on the device orientation.  No other wearable pain relief device has position dependent stimulation control t...

    09/4/2020NURO
    NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference

    WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S. for frontline practitioners treating acute and chronic pain. The poster is titled "Real-World Outcomes from High-Dose Transcutaneous Electrical Nerve Stimulation in Individuals With Chronic Knee Pain".  The poster presents an a...

    09/1/2020NURO
    NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity

    WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies.  It is often used to stage the severity of DPN, which is the most common specific cause of peripheral nerv...